Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Daiichi Sankyo
Daiichi Sankyo
Activities:
Packaging
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Therapeutic: datopotamab deruxtecan for breast cancer
Of all the various forms of breast cancer, triple negative is the most aggressive subtype
Research & Development
AstraZeneca and Daiichi Sankyo reveal phase 3 lung cancer study
Results for the TROP2-directed antibody drug conjugate demonstrated statistically significant improvement in progression-free survival vs. standard chemotherapy
Drug Delivery
ProLynx collaborates with Daiichi Sankyo on drug delivery
The collaboration will evaluate the utility of the releasable linker technology in half-life extension of small-molecule drugs after intravitreal injection
Finance
Heptares Therapeutics enters agreement with Daichi Sankyo
The collaboration aims to discover and develop novel, small-molecules for the treatment of pain
Pharmaceutical
Amgen and Daiichi Sankyo to commercialise biosimilars in Japan
The exclusive agreement includes nine biosimilars in late-stage development
Drug Delivery
Nitto Denko enters drug delivery partnership with Daiichi Sankyo
To accelerate the commercialisation of Nitto’s PassPort transdermal drug delivery technology
Research & Development
Daiichi Sankyo appoints Antoine Yver as Global Head, Oncology Research and Development
He will lead all global R&D across the oncology therapeutic area
Subscribe now